Physician profile
Eddie C Pyune
NPI 1457445124
$22,110.54
in general payments reported to CMS, 2019-2025
41 companies · $2,160 in 2025
The $2,160 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,237 · 2020: $3,273 · 2021: $4,501 · 2022: $3,177 · 2023: $2,425 · 2024: $3,339 · 2025: $2,160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,923.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,923.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $4,016.07 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $2,573.21 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,105.17 | 2019-2025 | Farxiga, Airsupra, Fasenra |
| Novartis Pharmaceuticals Corporation | $1,084.00 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $992.25 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $985.81 | 2019-2025 | Jardiance, Mounjaro, Kisunla |
| Scilex Pharmaceuticals INC. | $784.14 | 2019-2025 | Ztlido |
| Amarin Pharma, INC. | $683.83 | 2019-2022 | |
| Novo Nordisk INC | $668.28 | 2019-2024 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $660.73 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Aimmune Therapeutics, INC. | $646.06 | 2024-2025 | Zenpep |
| Takeda Pharmaceuticals U.S.A., INC. | $642.45 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $524.60 | 2019-2020 | |
| Ardelyx, INC. | $502.27 | 2024-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $482.12 | 2019-2023 | Xifaxan |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $453.92 | 2019-2021 | |
| Radius Health, INC. | $448.79 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $423.26 | 2020-2023 | |
| Dexcom, INC. | $399.92 | 2021-2025 | Dexcom G6 Transmitter |
| Allergan, INC. | $399.71 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $265.02 | 2022-2023 | |
| Sunovion Pharmaceuticals INC. | $264.41 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $260.66 | 2024 | Voquezna |
| Esperion Therapeutics, INC. | $223.52 | 2021-2024 | Nexletol |
| Pfizer INC. | $213.30 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $209.96 | 2019-2024 | Linzess |
| Sumitomo Pharma America, INC. | $144.78 | 2023-2025 | Gemtesa |
| Astellas Pharma US INC | $144.10 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $138.63 | 2019-2023 | Livalo, Seglentis |
| Merck Sharp & Dohme LLC | $127.88 | 2019-2024 | Verquvo |
| Xeris Pharmaceuticals, INC. | $126.28 | 2024 | Gvoke Hypopen |
| Redhill Biopharma INC. | $108.48 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $90.82 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $77.46 | 2020 | |
| Vivus LLC | $61.35 | 2021-2023 | Qsymia |
| Ibsa Pharma INC. | $48.51 | 2021-2023 | Tirosint, Licart |
| Exact Sciences Corporation | $36.14 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Azurity Pharmaceuticals, INC. | $29.16 | 2025 | Edarbi |
| Corium, LLC | $27.08 | 2023 | Adlarity |
| Idorsia Pharmaceuticals US INC | $18.43 | 2023 | Quviviq |
| Genentech USA, INC. | $17.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eddie Pyune listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.